TGFBR2 and Alzheimer disease: No data is yet available in the published literature on the role of hsa-mir-373-3p in AD; however, a recent study indicated that hsa-mir-373-3p inhibits epithelial–mesenchymal transition in choriocarcinoma through targeting TGFβR2 [63].